VXRT News and Press, Vaxart Inc. From 08/02/21

Shares of Vaxart (Nasdaq: VXRT) rose on Monday after the biotech said the U.S. Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application for its oral coronavirus vaccine. As of 2:20 p.m. EDT, Vaxart's stock price was up more than 12%. Vaxart's...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The vaccine industry is not one to be counted out, even as more and more Americans become inoculated against the novel coronavirus. There are still swaths of U.S. citizens that need to be vaccinated, as well as those abroad...

Ever-Glory EVK +75% announces $5 million share buyback plan Exicure (NASDAQ:XCUR) +36% and Ipsen enter into exclusive collaboration targeting rare neurodegenerative disorders AgriFORCE (AGRI) +20%. Autolus Therapeutics (NASDAQ:AUTL) +18%. and Moderna sign Option and License Agr...

Vaxart (NASDAQ:VXRT) soars 11.8% premarket after announcing that the FDA has cleared its Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate. "Together, the S-only and S+N constructs are part of our unique oral tablet COVID-19 vaccine candidat...

FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate Vaccine candidate expressing S-only protein produced higher serum antibodies than construct expressing both S and N in NHP study Phase II clinical trial with S-only candidate to begin in 2H...

The U.S. will not see lockdowns again to curb COVID-19 but "things are going to get worse" as the Delta variant fuels a surge in cases, said Dr. Anthony Fauci, Reuters reports. “I think we have enough of the percentage of people in the country — not enough to crush the outbreak ...

On Friday, the Centers for Disease Control and Prevention (CDC) released data supporting the view that the COVID-19 Delta variant can cause infections even among fully vaccinated people. The CDC report was based on a COVID-19 outbreak in Massachusetts, where 69% of the eligible population are...

Vaxart (NASDAQ:VXRT) has climbed ~11.8% in the pre-market after the company said its oral vaccine platform boosted the immune response in those who were vaccinated with its oral vaccine more than a year earlier. The results came from a Phase 1b study involving 12 subjects who w...

Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine First booster clinical study by Vaxart shows boosted immune responses similar to original responses with Vaxart vaccine Findings have potential implications for Vaxart's COVID-19 o...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips I’ll admit, it’s hard for me not to be massively bullish on California-based biotech company Vaxart  (NASDAQ: VXRT ) stock. Source: Ascannio / Shutterstock.com With the exception of occasional ...